Literature DB >> 17445545

Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma.

Federica Ermetici1, Alexis E Malavazos, Sabrina Corbetta, Lelio Morricone, Chiara Dall'Asta, Massimiliano M Corsi, Bruno Ambrosi.   

Abstract

Adrenal incidentalomas (AIs) have been associated with an increased incidence of several cardiovascular risk factors, similar to overt Cushing syndrome. Data about the involvement of the adipokines in the development of insulin resistance and atherosclerosis in AI are completely lacking. The aim of the present study was to evaluate plasma interleukin 6 (IL-6), adiponectin, resistin, tumor necrosis factor alpha (TNF-alpha), and monocyte chemoattractant protein 1 (MCP-1) levels in patients with AI. Plasma IL-6, adiponectin, resistin, TNF-alpha, and MCP-1 levels were measured in 20 healthy subjects (6 males; 14 females; age, 58.5 +/- 2.2 years; body mass index, 28.1 +/- 0.9 kg/m(2)) and in 20 patients (5 males; 15 females; age, 57.9 +/- 2.0 years; body mass index, 28.0 +/- 0.8 kg/m(2)) with AI and typical computed tomographic features of cortical adenoma, who were not affected by diabetes mellitus, hypertension, or other relevant diseases. All patients underwent anthropometric measurements and determination of basal corticotropin, cortisol, and urinary free cortisol excretion. Overnight dexamethasone test and 250-microg corticotropin test were performed in all cases. A subclinical Cushing syndrome was found in 3 patients, whereas the others had apparently nonfunctioning masses. Plasma IL-6, adiponectin, resistin, TNF-alpha, and MCP-1 levels were higher in patients than in controls (64.4 +/- 2.8 vs 5.5 +/- 0.6 pg/mL, 13.7 +/- 1.3 vs 3.6 +/- 0.5 microg/mL, 12.5 +/- 1.9 vs 5.1 +/- 0.2 ng/mL, 27.0 +/- 1.5 vs 22.2 +/- 1.5 pg/mL, 172.5 +/- 20.0 vs 104.4 +/- 19.5 pg/mL, respectively; P < .05) and apparently not affected by the presence of visceral obesity. Plasma IL-6 levels were negatively correlated with urinary free cortisol (r = -0.461, P < .05), and TNF-alpha levels were positively correlated with cortisol after the administration of 1 mg dexamethasone (r = 0.636, P < .01). In conclusion, patients with AI may show increased levels of adipokines (apparently not related to the presence of diabetes, hypertension, or obesity), which may be affected by the presence of the adrenal adenoma. For some adipokines, a direct production from the adrenal gland may be hypothesized even if other studies are needed to better investigate the role of adipokines in states of altered cortisol secretion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445545     DOI: 10.1016/j.metabol.2006.12.018

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  17 in total

1.  Is there an association between non-functioning adrenal adenoma and endothelial dysfunction?

Authors:  S Yener; M Baris; M Secil; B Akinci; A Comlekci; S Yesil
Journal:  J Endocrinol Invest       Date:  2010-06-04       Impact factor: 4.256

2.  The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test.

Authors:  Mariana Arruda; Emanuela Mello Ribeiro Cavalari; Marcela Pessoa de Paula; Felipe Fernandes Cordeiro de Morais; Guilherme Furtado Bilro; Maria Caroline Alves Coelho; Nathalie Anne de Oliveira E Silva de Morais; Diana Choeri; Aline Moraes; Leonardo Vieira Neto
Journal:  J Hum Hypertens       Date:  2017-11-24       Impact factor: 3.012

3.  Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up.

Authors:  F Ceccato; G Occhi; N M Albiger; S Rizzati; S Ferasin; G Trivellin; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

4.  Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis.

Authors:  Mazhar Müslüm Tuna; Narin Nasıroğlu Imga; Berçem Ayçiçek Doğan; Fatma Meriç Yılmaz; Canan Topçuoğlu; Gülhan Akbaba; Dilek Berker; Serdar Güler
Journal:  J Endocrinol Invest       Date:  2014-06-13       Impact factor: 4.256

5.  Cortisol level after dexamethasone suppression test in patients with non-functioning adrenal incidentaloma is positively associated with the duration of reactive hyperemia response on microvascular bed.

Authors:  M P de Paula; A B Moraes; M das Graças Coelho de Souza; E M R Cavalari; R C Campbell; G da Silva Fernandes; M L F Farias; L M C Mendonça; M Madeira; E Bouskela; L G Kraemer-Aguiar; L Vieira Neto
Journal:  J Endocrinol Invest       Date:  2020-07-19       Impact factor: 4.256

6.  Clinically silent adrenal adenomas - their relation to the metabolic syndrome and to GNB3 C825T gene polymorphism.

Authors:  Ivica Lazúrová; Daniela Spišáková; Hedviga Wagnerová; Viera Habalová; Ingrid Dravecká; Petrášová Darina; Ivica Drahovská; Lýdia Pundová
Journal:  Wien Klin Wochenschr       Date:  2011-10-10       Impact factor: 1.704

7.  Effects of short-term corticoid ingestion on food intake and adipokines in healthy recreationally trained men.

Authors:  N Rieth; L Jollin; B Le Panse; A-M Lecoq; A Arlettaz; J De Ceaurriz; K Collomp
Journal:  Eur J Appl Physiol       Date:  2008-11-05       Impact factor: 3.078

Review 8.  Skeletal muscle insulin resistance in endocrine disease.

Authors:  Melpomeni Peppa; Chrysi Koliaki; Panagiotis Nikolopoulos; Sotirios A Raptis
Journal:  J Biomed Biotechnol       Date:  2010-03-15

9.  Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma.

Authors:  Serkan Yener; Sinan Genc; Baris Akinci; Mustafa Secil; Tevfik Demir; Abdurrahman Comlekci; Senem Ertilav; Sena Yesil
Journal:  Endocrine       Date:  2009-03-10       Impact factor: 3.633

10.  Non-functioning adrenal incidentalomas are associated with elevated D-dimer levels.

Authors:  S Yener; A Comlekci; B Akinci; M Secil; T Demir; S Ertilav; S Yesil
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.